vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v24i3.2910vsp-3773Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWУвеиты, ассоциированные с ювенильным идиопатическим артритом. Современные подходы к терапии: обзор литературыJuvenile Idiopathic Arthritis Associated Uveitis. Modern Therapy Approaches: Narrative Reviewhttps://orcid.org/0000-0002-1061-6074ЯковлевА. А.YakovlevAlexandr A.

Санкт-Петербург

Saint Petersburg

https://orcid.org/0000-0001-6758-6999НикитинаТ. Н.NikitinaTatiana N.

Санкт-Петербург

Saint Petersburg

https://orcid.org/0000-0002-1180-8086КостикМ. М.KostikMikhail M.

Костик Михаил Михайлович - доктор медицинских наук, профессор кафедры госпитальной педиатрии.

194100, Санкт-Петербург, ул. Литовская, д. 2

тел.: +7 (812) 416-52-96

Saint Petersburg

kost-mikhail@yandex.ruСанкт-Петербургский государственный медицинский педиатрический университетРоссияSaint Petersburg State Pediatric Medical UniversityRussian Federation202521072025243162177Copyright © Яковлев А.А., Никитина Т.Н., Костик М.М., 20252025Яковлев А.А., Никитина Т.Н., Костик М.М.Yakovlev A.A., Nikitina T.N., Kostik M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3773

Увеиты, ассоциированные с ювенильным идиопатическим артритом (ЮИА) — это наиболее частое внесуставное проявление ЮИА. В настоящее время, несмотря на трудности в диагностике, был разработан общий подход к терапии этого состояния, что позволяет избежать многих долгосрочных осложнений и повысить качество жизни пациентов. Быстрое развитие фармакотерапии, в том числе появление новых иммуносупрессивных и генно-инженерных биологических препаратов, расширяет терапевтический арсенал и повышает шансы на достижение стойкой ремиссии, хотя остается еще немало вопросов относительно безопасности многих генно-инженерных биологических препаратов, оптимального времени отмены терапии и долгосрочного катамнеза у пациентов с ЮИА. В представленном обзоре обобщены и проанализированы современные данные, касающиеся подходов к лечению, эффективности и безопасности терапии, а также перспектив ведения пациентов с увеитом при ЮИА.

Juvenile idiopathic arthritis (JIA) associated uveitis is the most common extra-articular manifestation of JIA. Nowadays, unified approach for the management of this condition has been developed despite all the difficulties in diagnosis. It allows to avoid many long-term complications and improves patients’ quality of life. Rapid development of pharmacotherapy (including appearance of new immunosuppressive and genetically engineered biologic drugs) expands the therapeutic methods and increases the chances in achieving sustained remission. However, still there are many questions regarding genetically engineered biologic drugs safety, optimal time to treatment cessation, and long-term follow-up in patients with JIA. This review summarizes and analyzes modern data regarding treatment approaches, therapy efficacy and safety, and perspectives for managing patients with uveitis and JIA.

увеитиридоциклитювенильный идиопатический артриттерапиягенно-инженерная биологическая терапияантитела против фактора некроза опухоли альфаuveitisiridocyclitisjuvenile idiopathic arthritistherapygenetically engineered biologic drugsanti-tumor necrosis factor alpha antibodiesReferencesRavelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: https://doi.org/10.1016/S0140-6736(07)60363-8Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: https://doi.org/10.1016/S0140-6736(07)60363-8Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi: https://doi.org/10.1016/j.clim.2019.108322Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi: https://doi.org/10.1016/j.clim.2019.108322Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703–716. doi: https://doi.org/10.1002/acr.23871Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703–716. doi: https://doi.org/10.1002/acr.23871Chen WD, Wu CH, Wu PY, et al. Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis. J Formos Med Assoc. 2024;123(12):1218–1227. doi: https://doi.org/10.1016/j.jfma.2024.02.010Chen WD, Wu CH, Wu PY, et al. Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis. J Formos Med Assoc. 2024;123(12):1218–1227. doi: https://doi.org/10.1016/j.jfma.2024.02.010Foeldvari I, Maccora I, Petrushkin H, et al. New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975–982. doi: https://doi.org/10.1002/acr.24963Foeldvari I, Maccora I, Petrushkin H, et al. New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975–982. doi: https://doi.org/10.1002/acr.24963Увеиты неинфекционные: клинические рекомендации / Ассоциация врачей-офтальмологов; Общество офтальмологов России // Рубрикатор клинических рекомендаций: официальный сайт. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/787_1. Ссылка активна на 03.03.2025.Uveity neinfektsionnye: Clinical guidelines. Association of ophthalmologists, Society of ophthalmologists of Russia. In: Rubrikator klinicheskikh rekomendatsii: Official website. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/787_1. Ссылка активна на 03.03.2025.Увеиты, ассоциированные с ювенильным идиопатическим артритом: клинические рекомендации / Ассоциация врачей-офтальмологов. — Минздрав России; 2017. Доступно по: https://eyepress.ru/sbornik.aspx?668. Ссылка активна на 03.03.2025.Uveity, assotsiirovannye s yuvenil’nym idiopaticheskim artritom: Clinical guidelines. Association of ophthalmologists. Ministry of Health of the Russian Federation; 2017. (In Russ). Доступно по: https://eyepress.ru/sbornik.aspx?668. Ссылка активна на 03.03.2025.Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117. doi: https://doi.org/10.1136/annrheumdis-2018-213131Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117. doi: https://doi.org/10.1136/annrheumdis-2018-213131Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785. doi: https://doi.org/10.1007/s00296-015-3231-3Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785. doi: https://doi.org/10.1007/s00296-015-3231-3Neves LM, Haefeli LM, Hopker LM, et al. Monitoring and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis: Brazilian Evidence-based Practice Guidelines. Ocul Immunol Inflamm. 2022;30(6):1384–1398. doi: https://doi.org/10.1080/09273948.2021.1876886Neves LM, Haefeli LM, Hopker LM, et al. Monitoring and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis: Brazilian Evidence-based Practice Guidelines. Ocul Immunol Inflamm. 2022;30(6):1384–1398. doi: https://doi.org/10.1080/09273948.2021.1876886Kothari S, Foster CS, Pistilli M, et al. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015;122(10):1987–2001. doi: https://doi.org/10.1016/j.ophtha.2015.06.041Kothari S, Foster CS, Pistilli M, et al. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015;122(10):1987–2001. doi: https://doi.org/10.1016/j.ophtha.2015.06.041Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43–55. doi: https://doi.org/10.1016/j.semarthrit.2018.11.004Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43–55. doi: https://doi.org/10.1016/j.semarthrit.2018.11.004Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi: https://doi.org/10.1016/j.ophtha.2009.12.003Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi: https://doi.org/10.1016/j.ophtha.2009.12.003Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: https://doi.org/10.1016/j.ajo.2005.03.057Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: https://doi.org/10.1016/j.ajo.2005.03.057Roesel M, Gutfleisch M, Heinz C, et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42(2):81–86. doi: https://doi.org/10.1159/000220600Roesel M, Gutfleisch M, Heinz C, et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42(2):81–86. doi: https://doi.org/10.1159/000220600Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12(3):169–192. doi: https://doi.org/10.1080/092739490500192Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12(3):169–192. doi: https://doi.org/10.1080/092739490500192Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104(6):847–851. doi: https://doi.org/10.1001/archopht.1986.01050180081035Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104(6):847–851. doi: https://doi.org/10.1001/archopht.1986.01050180081035Pichi F, Nucci P, Baynes K, et al. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37(1):221–228. doi: https://doi.org/10.1007/s10792-016-0265-9Pichi F, Nucci P, Baynes K, et al. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37(1):221–228. doi: https://doi.org/10.1007/s10792-016-0265-9Cordero-Coma M, Garzo I, Calleja S, et al. Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS. 2013;17(6):632–634. doi: https://doi.org/10.1016/j.jaapos.2013.07.014Cordero-Coma M, Garzo I, Calleja S, et al. Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS. 2013;17(6):632–634. doi: https://doi.org/10.1016/j.jaapos.2013.07.014Carlsson E, Beresford MW, Ramanan AV, et al. Juvenile Idiopathic Arthritis Associated Uveitis. Children (Basel). 2021;8(8):646. doi: https://doi.org/10.3390/children8080646Carlsson E, Beresford MW, Ramanan AV, et al. Juvenile Idiopathic Arthritis Associated Uveitis. Children (Basel). 2021;8(8):646. doi: https://doi.org/10.3390/children8080646Kim L, Li A, Angeles-Han S, et al. Update on the management of uveitis in children: an overview for the clinician. Expert Rev Ophthalmol. 2019;14(4-5):211–218. doi: https://doi.org/10.1080/17469899.2019.1663731Kim L, Li A, Angeles-Han S, et al. Update on the management of uveitis in children: an overview for the clinician. Expert Rev Ophthalmol. 2019;14(4-5):211–218. doi: https://doi.org/10.1080/17469899.2019.1663731Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52(5):825–831. doi: https://doi.org/10.1093/rheumatology/kes186Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52(5):825–831. doi: https://doi.org/10.1093/rheumatology/kes186Wieringa WG, Armbrust W, Legger GE, Los LI. Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis. Ocul Immunol Inflamm. 2019;27(8):1305–1313. doi: https://doi.org/10.1080/09273948.2018.1529800Wieringa WG, Armbrust W, Legger GE, Los LI. Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis. Ocul Immunol Inflamm. 2019;27(8):1305–1313. doi: https://doi.org/10.1080/09273948.2018.1529800Zu Hoerste MM, Walscheid K, Tappeiner C, et al. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985–1992. doi: https://doi.org/10.1007/s00417-018-4082-xZu Hoerste MM, Walscheid K, Tappeiner C, et al. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985–1992. doi: https://doi.org/10.1007/s00417-018-4082-xPichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563–571.Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563–571.Tuková J, Chládek J, Nemcová D, et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009;27(6):1047–1053.Tuková J, Chládek J, Nemcová D, et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009;27(6):1047–1053.van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S27–S32.van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S27–S32.van Straalen JW, Akay G, Kouwenberg CV, et al. Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open. 2023;9(2):e003010. doi: https://doi.org/10.1136/rmdopen-2023-003010van Straalen JW, Akay G, Kouwenberg CV, et al. Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open. 2023;9(2):e003010. doi: https://doi.org/10.1136/rmdopen-2023-003010Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality? Ocul Immunol Inflamm. 2022;30(7-8):1763–1767. doi: https://doi.org/10.1080/09273948.2021.1951303Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality? Ocul Immunol Inflamm. 2022;30(7-8):1763–1767. doi: https://doi.org/10.1080/09273948.2021.1951303Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34(4):714–718.Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34(4):714–718.Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163(3):879–884. doi: https://doi.org/10.1016/j.jpeds.2013.03.047Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163(3):879–884. doi: https://doi.org/10.1016/j.jpeds.2013.03.047Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–213. doi: https://doi.org/10.1136/bjo.2009.173542Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–213. doi: https://doi.org/10.1136/bjo.2009.173542Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for Ocular Inflammatory Diseases. Am J Ophthalmol. 2009;148(4): 500–509.e2. doi: https://doi.org/10.1016/j.ajo.2009.05.008Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for Ocular Inflammatory Diseases. Am J Ophthalmol. 2009;148(4): 500–509.e2. doi: https://doi.org/10.1016/j.ajo.2009.05.008Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol. 1997;24(12):2444–2450.Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol. 1997;24(12):2444–2450.Maleki A, Anesi SD, Look-Why S, et al. Pediatric uveitis: A comprehensive review. Surv Ophthalmol. 2022;67(2):510–529. doi: https://doi.org/10.1016/j.survophthal.2021.06.006Maleki A, Anesi SD, Look-Why S, et al. Pediatric uveitis: A comprehensive review. Surv Ophthalmol. 2022;67(2):510–529. doi: https://doi.org/10.1016/j.survophthal.2021.06.006Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(4):427–435. doi: https://doi.org/10.1038/eye.2011.23Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(4):427–435. doi: https://doi.org/10.1038/eye.2011.23Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2): 180–184. doi: https://doi.org/10.1136/bjo.2006.094698Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2): 180–184. doi: https://doi.org/10.1136/bjo.2006.094698Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–1421.e1. doi: https://doi.org/10.1016/j.ophtha.2007.12.011Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–1421.e1. doi: https://doi.org/10.1016/j.ophtha.2007.12.011Cantarini L, Simonini G, Frediani B, et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs. 2012;21(1):1–6. doi: https://doi.org/10.1517/13543784.2012.636350Cantarini L, Simonini G, Frediani B, et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs. 2012;21(1):1–6. doi: https://doi.org/10.1517/13543784.2012.636350Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019;322(10):936–945. doi: https://doi.org/10.1001/jama.2019.12618Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019;322(10):936–945. doi: https://doi.org/10.1001/jama.2019.12618Reddy AK, Miller DC, Sura AA, et al. Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. J Ophthalmic Inflamm Infect. 2023;13(1):29. doi: https://doi.org/10.1186/s12348-023-00350-5Reddy AK, Miller DC, Sura AA, et al. Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. J Ophthalmic Inflamm Infect. 2023;13(1):29. doi: https://doi.org/10.1186/s12348-023-00350-5Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870. doi: https://doi.org/10.1016/j.ophtha.2014.04.023Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870. doi: https://doi.org/10.1016/j.ophtha.2014.04.023Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734. doi: https://doi.org/10.1002/acr.23870Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734. doi: https://doi.org/10.1002/acr.23870Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34(11):1839–1846. doi: https://doi.org/10.1007/s10067-015-3029-4Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34(11):1839–1846. doi: https://doi.org/10.1007/s10067-015-3029-4Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277–1279.Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277–1279.Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340–343. doi: https://doi.org/10.1038/eye.2000.84Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340–343. doi: https://doi.org/10.1038/eye.2000.84Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol. 1997;15(2):71–75.Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol. 1997;15(2):71–75.Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326(25):1654–1660. doi: https://doi.org/10.1056/NEJM199206183262502Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326(25):1654–1660. doi: https://doi.org/10.1056/NEJM199206183262502Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2): 138–146. doi: https://doi.org/10.1016/s0002-9394(14)76692-9Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2): 138–146. doi: https://doi.org/10.1016/s0002-9394(14)76692-9Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009;23(5): 1192–1198. doi: https://doi.org/10.1038/eye.2008.174Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009;23(5): 1192–1198. doi: https://doi.org/10.1038/eye.2008.174Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006. doi: https://doi.org/10.1016/j.ophtha.2007.01.026Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006. doi: https://doi.org/10.1016/j.ophtha.2007.01.026Dini G, Dell’Isola GB, Beccasio A, et al. Biologic therapies for juvenile idiopathic arthritis-associated uveitis. Front Ophthalmol (Lausanne). 2022;2:954901. doi: https://doi.org/10.3389/fopht.2022.954901Dini G, Dell’Isola GB, Beccasio A, et al. Biologic therapies for juvenile idiopathic arthritis-associated uveitis. Front Ophthalmol (Lausanne). 2022;2:954901. doi: https://doi.org/10.3389/fopht.2022.954901Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255. doi: https://doi.org/10.1159/000055677Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255. doi: https://doi.org/10.1159/000055677Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155–157. doi: https://doi.org/10.1185/030079903125002847Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155–157. doi: https://doi.org/10.1185/030079903125002847Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637. doi: https://doi.org/10.1016/j.preteyeres.2004.06.005Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637. doi: https://doi.org/10.1016/j.preteyeres.2004.06.005Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35(11):3884–3889.Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35(11):3884–3889.Sen ES, Ramanan AV. New age of biological therapies in paediatric rheumatology. Arch Dis Child. 2014;99(7):679–685. doi: https://doi.org/10.1136/archdischild-2013-304396Sen ES, Ramanan AV. New age of biological therapies in paediatric rheumatology. Arch Dis Child. 2014;99(7):679–685. doi: https://doi.org/10.1136/archdischild-2013-304396Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK482425. Accessed on Marth 05, 2023.Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/ books/NBK482425. Accessed on Marth 05, 2023.Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67(11): 1529–1535. doi: https://doi.org/10.1002/acr.22613Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67(11): 1529–1535. doi: https://doi.org/10.1002/acr.22613Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073–1084. doi: https://doi.org/10.1002/acr.22214Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073–1084. doi: https://doi.org/10.1002/acr.22214Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. doi: https://doi.org/10.1002/art.20904Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. doi: https://doi.org/10.1002/art.20904Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022;10(10):CD013818. doi: https://doi.org/10.1002/14651858.CD013818.pub2Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022;10(10):CD013818. doi: https://doi.org/10.1002/14651858.CD013818.pub2Li Y, Mao X, Tang X, Mao H. Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Rheumatol Ther. 2021;8(2):711–727. doi: https://doi.org/10.1007/s40744-021-00296-xLi Y, Mao X, Tang X, Mao H. Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Rheumatol Ther. 2021;8(2):711–727. doi: https://doi.org/10.1007/s40744-021-00296-xU.S. Food and Drug Administration. Highlights of Prescribing Information: HUMIRA (Adalimumab). FDA; 2023. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf. Accessed on May 03, 2025.U.S. Food and Drug Administration. Highlights of Prescribing Information: HUMIRA (Adalimumab). FDA; 2023. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf. Accessed on May 03, 2025.Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10: 2997–3003. doi: https://doi.org/10.2147/DDDT.S94188Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10: 2997–3003. doi: https://doi.org/10.2147/DDDT.S94188Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019;23(15): 1–140. doi: https://doi.org/10.3310/hta23150Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019;23(15): 1–140. doi: https://doi.org/10.3310/hta23150Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022;100(4):e994–e1001. doi: https://doi.org/10.1111/aos.15012Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022;100(4):e994–e1001. doi: https://doi.org/10.1111/aos.15012Choe S, Heo JW, Oh BL. Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis. Korean J Ophthalmol. 2020;34(4):274–280. doi: https://doi.org/10.3341/kjo.2020.0005Choe S, Heo JW, Oh BL. Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis. Korean J Ophthalmol. 2020;34(4):274–280. doi: https://doi.org/10.3341/kjo.2020.0005Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011. doi: https://doi.org/10.1136/annrheumdis-2017-212089Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011. doi: https://doi.org/10.1136/annrheumdis-2017-212089Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–1646. doi: https://doi.org/10.1056/NEJMoa1614160Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–1646. doi: https://doi.org/10.1056/NEJMoa1614160Suhler EB, Adán A, Brézin AP, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125(7): 1075–1087. doi: https://doi.org/10.1016/j.ophtha.2017.12.039Suhler EB, Adán A, Brézin AP, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125(7): 1075–1087. doi: https://doi.org/10.1016/j.ophtha.2017.12.039Ming S, Xie K, He H, et al. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005–2016. doi: https://doi.org/10.2147/DDDT.S160431Ming S, Xie K, He H, et al. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005–2016. doi: https://doi.org/10.2147/DDDT.S160431Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi: https://doi.org/10.1016/j.ophtha.2012.02.018Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi: https://doi.org/10.1016/j.ophtha.2012.02.018Lazarević D, Ratković Janković M, et al. Long-term efficacy and safety of adalimumab in juvenile idiopathic arthritis (JIA) associated uveitis. Acta Med Medianae. 2021;60(3):30–36. doi: https://doi.org/10.5633/amm.2021.0304Lazarević D, Ratković Janković M, et al. Long-term efficacy and safety of adalimumab in juvenile idiopathic arthritis (JIA) associated uveitis. Acta Med Medianae. 2021;60(3):30–36. doi: https://doi.org/10.5633/amm.2021.0304Sheppard J, Joshi A, Betts KA, et al. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017;135(6):511–518. doi: https://doi.org/10.1001/jamaophthalmol.2017.0603Sheppard J, Joshi A, Betts KA, et al. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017;135(6):511–518. doi: https://doi.org/10.1001/jamaophthalmol.2017.0603Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: https://doi.org/10.1016/S0140-6736(16)31339-3Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: https://doi.org/10.1016/S0140-6736(16)31339-3Ucan Gunduz G, Yalcinbayir O, Cekic S, et al. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. J Ocul Pharmacol Ther. 2021;37(4):236–240. doi: https://doi.org/10.1089/jop.2020.0081Ucan Gunduz G, Yalcinbayir O, Cekic S, et al. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. J Ocul Pharmacol Ther. 2021;37(4):236–240. doi: https://doi.org/10.1089/jop.2020.0081Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–344. doi: https://doi.org/10.1093/rheumatology/kem356Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–344. doi: https://doi.org/10.1093/rheumatology/kem356Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16. doi: https://doi.org/10.1186/1546-0096-11-16Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16. doi: https://doi.org/10.1186/1546-0096-11-16Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37(5): 1407–1411. doi: https://doi.org/10.1007/s10067-018-4057-7Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37(5): 1407–1411. doi: https://doi.org/10.1007/s10067-018-4057-7Brunelli JB, Silva CA, Pasoto SG, et al. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol. 2020;39(2):515–521. doi: https://doi.org/10.1007/s10067-019-04798-6Brunelli JB, Silva CA, Pasoto SG, et al. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol. 2020;39(2):515–521. doi: https://doi.org/10.1007/s10067-019-04798-6Phatak S, Agrawal R, Pavesio C. Adalimumab: viable treatment option for pediatric refractory uveitis? Expert Rev Ophthalmol. 2014;9(3):175–184. doi: https://doi.org/10.1586/17469899.2014.903801Phatak S, Agrawal R, Pavesio C. Adalimumab: viable treatment option for pediatric refractory uveitis? Expert Rev Ophthalmol. 2014;9(3):175–184. doi: https://doi.org/10.1586/17469899.2014.903801Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2019;71(4): 482–491. doi: https://doi.org/10.1002/acr.23610Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2019;71(4): 482–491. doi: https://doi.org/10.1002/acr.23610Huard J, Mihailescu SD, Muraine M, et al. Effectiveness and Safety of Weekly Adalimumab for Non-Infectious Chronic Anterior Uveitis in Children. Ocul Immunol Inflamm. 2023;31(10):2039– 2049. doi: https://doi.org/10.1080/09273948.2023.2279682Huard J, Mihailescu SD, Muraine M, et al. Effectiveness and Safety of Weekly Adalimumab for Non-Infectious Chronic Anterior Uveitis in Children. Ocul Immunol Inflamm. 2023;31(10):2039– 2049. doi: https://doi.org/10.1080/09273948.2023.2279682Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549–553. doi: https://doi.org/10.1007/s10067-017-3890-4Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549–553. doi: https://doi.org/10.1007/s10067-017-3890-4Hughes DA, Culeddu G, Plumpton CO, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2019;126(3): 415–424. doi: https://doi.org/10.1016/j.ophtha.2018.09.043Hughes DA, Culeddu G, Plumpton CO, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2019;126(3): 415–424. doi: https://doi.org/10.1016/j.ophtha.2018.09.043Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589. doi: https://doi.org/10.1016/j.survophthal.2015.06.004Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589. doi: https://doi.org/10.1016/j.survophthal.2015.06.004Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324. doi: https://doi.org/10.1136/bjo.2006.103721Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324. doi: https://doi.org/10.1136/bjo.2006.103721Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33(5):461–468. doi: https://doi.org/10.1111/j.1442-9071.2005.01062.xRichards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33(5):461–468. doi: https://doi.org/10.1111/j.1442-9071.2005.01062.xSimonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618. doi: https://doi.org/10.1002/acr.20404Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618. doi: https://doi.org/10.1002/acr.20404Mase O, Qasem M, Beare N. Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis. BMJ Open Ophthalmol. 2023;8(1):e001303. doi: https://doi.org/10.1136/bmjophth-2023-001303Mase O, Qasem M, Beare N. Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis. BMJ Open Ophthalmol. 2023;8(1):e001303. doi: https://doi.org/10.1136/bmjophth-2023-001303Jari M, Shiari R, Salehpour O, Rahmani K. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):41. doi: https://doi.org/10.1186/s13023-020-1324-xJari M, Shiari R, Salehpour O, Rahmani K. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):41. doi: https://doi.org/10.1186/s13023-020-1324-xLiu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2023;23(1):240. doi: https://doi.org/10.1186/s12886-023-02987-1Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2023;23(1):240. doi: https://doi.org/10.1186/s12886-023-02987-1Kreps EO, Epps SJ, Consejo A, et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye (Lond). 2024;38(5):871–876. doi: https://doi.org/10.1038/s41433-023-02795-3Kreps EO, Epps SJ, Consejo A, et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye (Lond). 2024;38(5):871–876. doi: https://doi.org/10.1038/s41433-023-02795-3Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J. 2019;17(1):79. doi: https://doi.org/10.1186/s12969-019-0383-9Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J. 2019;17(1):79. doi: https://doi.org/10.1186/s12969-019-0383-9Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844–849. doi: https://doi.org/10.1016/j.ajo.2007.08.018Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844–849. doi: https://doi.org/10.1016/j.ajo.2007.08.018Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi: https://doi.org/10.3899/jrheum.120583Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi: https://doi.org/10.3899/jrheum.120583Cecchin V, Zannin ME, Ferrari D, et al. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45(8):1167–1172. doi: https://doi.org/10.3899/jrheum.171006Cecchin V, Zannin ME, Ferrari D, et al. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45(8):1167–1172. doi: https://doi.org/10.3899/jrheum.171006Maccora I, Fusco E, Marrani E, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford). 2021;60(2):568–587. doi: https://doi.org/10.1093/rheumatology/keaa595Maccora I, Fusco E, Marrani E, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford). 2021;60(2):568–587. doi: https://doi.org/10.1093/rheumatology/keaa595Jin Y, Lu S, Lin Y, Mou X. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology. 2022;30(4): 1363–1368. doi: https://doi.org/10.1007/s10787-022-01019-6Jin Y, Lu S, Lin Y, Mou X. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology. 2022;30(4): 1363–1368. doi: https://doi.org/10.1007/s10787-022-01019-6Okada K, Zhou Y, Hashida N, et al. The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis. Ocul Immunol Inflamm. 2023;31(5):1013–1023. doi: https://doi.org/10.1080/09273948.2022.2081584Okada K, Zhou Y, Hashida N, et al. The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis. Ocul Immunol Inflamm. 2023;31(5):1013–1023. doi: https://doi.org/10.1080/09273948.2022.2081584William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–233. doi: https://doi.org/10.1007/s12348-012-0081-yWilliam M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–233. doi: https://doi.org/10.1007/s12348-012-0081-yPalmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36(4):652–657.Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36(4):652–657.Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol Online J. 2021;19(1):132. doi: https://doi.org/10.1186/s12969-021-00630-1Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol Online J. 2021;19(1):132. doi: https://doi.org/10.1186/s12969-021-00630-1Tungsattayathitthan U, Tesavibul N, Choopong P, et al. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Sci Rep. 2024;14(1):2179. doi: https://doi.org/10.1038/s41598-024-52526-1Tungsattayathitthan U, Tesavibul N, Choopong P, et al. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Sci Rep. 2024;14(1):2179. doi: https://doi.org/10.1038/s41598-024-52526-1Yazgan S, Celik U, Işık M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139–145. doi: https://doi.org/10.1007/s10792-016-0239-yYazgan S, Celik U, Işık M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139–145. doi: https://doi.org/10.1007/s10792-016-0239-yMiserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95. doi: https://doi.org/10.3109/09273948.2013.844265Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95. doi: https://doi.org/10.3109/09273948.2013.844265Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825. doi: https://doi.org/10.1002/acr.20115Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825. doi: https://doi.org/10.1002/acr.20115Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297–300. doi: https://doi.org/10.1007/s00417-010-1523-6Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297–300. doi: https://doi.org/10.1007/s00417-010-1523-6Gaggiano C, Rigante D, Tosi GM, et al. Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. Clin Rheumatol. 2020;39(2):327–337. doi: https://doi.org/10.1007/s10067-019-04763-3Gaggiano C, Rigante D, Tosi GM, et al. Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. Clin Rheumatol. 2020;39(2):327–337. doi: https://doi.org/10.1007/s10067-019-04763-3Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42(4): 706–711. doi: https://doi.org/10.3899/jrheum.140410Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42(4): 706–711. doi: https://doi.org/10.3899/jrheum.140410Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. Front Pediatr. 2022;10:851453. doi: https://doi.org/10.3389/fped.2022.851453Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. Front Pediatr. 2022;10:851453. doi: https://doi.org/10.3389/fped.2022.851453Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–e406. doi: https://doi.org/10.1111/aos.13015Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–e406. doi: https://doi.org/10.1111/aos.13015Adán A, Moll-Udina A, Ramirez J, Llorenç V. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report. Ocul Immunol Inflamm. 2021;29(1):6–8. doi: https://doi.org/10.1080/09273948.2019.1644350Adán A, Moll-Udina A, Ramirez J, Llorenç V. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report. Ocul Immunol Inflamm. 2021;29(1):6–8. doi: https://doi.org/10.1080/09273948.2019.1644350Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632. doi: https://doi.org/10.1007/s00417-013-2436-yAdán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632. doi: https://doi.org/10.1007/s00417-013-2436-yMaleki A, Manhapra A, Asgari S, et al. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2021;29(1):14–20. doi: https://doi.org/10.1080/09273948.2020.1817501Maleki A, Manhapra A, Asgari S, et al. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2021;29(1):14–20. doi: https://doi.org/10.1080/09273948.2020.1817501Dipasquale V, Atteritano M, Fresta J, et al. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases. J Clin Pharm Ther. 2019;44(3):482–485. doi: https://doi.org/10.1111/jcpt.12821Dipasquale V, Atteritano M, Fresta J, et al. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases. J Clin Pharm Ther. 2019;44(3):482–485. doi: https://doi.org/10.1111/jcpt.12821Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69(3):668–675. doi: https://doi.org/10.1002/art.39940Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69(3):668–675. doi: https://doi.org/10.1002/art.39940Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94. doi: https://doi.org/10.1016/j.ajo.2018.12.019Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94. doi: https://doi.org/10.1016/j.ajo.2018.12.019Quesada-Masachs E, Caballero CM. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis. J Rheumatol. 2017;44(2):260–261. doi: https://doi.org/10.3899/jrheum.160908Quesada-Masachs E, Caballero CM. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis. J Rheumatol. 2017;44(2):260–261. doi: https://doi.org/10.3899/jrheum.160908Karaca I, Uludag G, Matsumiya W, et al. Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Eye (Lond). 2023;37(11):2197–2203. doi: https://doi.org/10.1038/s41433-022-02315-9Karaca I, Uludag G, Matsumiya W, et al. Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Eye (Lond). 2023;37(11):2197–2203. doi: https://doi.org/10.1038/s41433-022-02315-9Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016;43(12): 2183–2188. doi: https://doi.org/10.3899/jrheum.160231Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016;43(12): 2183–2188. doi: https://doi.org/10.3899/jrheum.160231Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi: https://doi.org/10.1016/S2665-9913(20)30008-4Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi: https://doi.org/10.1016/S2665-9913(20)30008-4Ramanan AV, Dick AD, Jones AP, et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4. doi: https://doi.org/10.1186/s41927-018-0010-2Ramanan AV, Dick AD, Jones AP, et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4. doi: https://doi.org/10.1186/s41927-018-0010-2Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47): 7359–7368. doi: https://doi.org/10.1038/sj.onc.1206939Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47): 7359–7368. doi: https://doi.org/10.1038/sj.onc.1206939Welzel T, Winskill C, Zhang N, et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology — what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: https://doi.org/10.1186/s12969-021-00514-4Welzel T, Winskill C, Zhang N, et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology — what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: https://doi.org/10.1186/s12969-021-00514-4Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390–1394. doi: https://doi.org/10.1093/rheumatology/ker107Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390–1394. doi: https://doi.org/10.1093/rheumatology/ker107Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35–39. doi: https://doi.org/10.1016/j.autrev.2011.07.001Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35–39. doi: https://doi.org/10.1016/j.autrev.2011.07.001Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786. doi: https://doi.org/10.1136/bjophthalmol-2015-306790Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786. doi: https://doi.org/10.1136/bjophthalmol-2015-306790Cao H, Ma X. Rituximab in the Treatment of Non-Infectious Uveitis: A Review. J Inflamm Res. 2024;17:6765–6780. doi: https://doi.org/10.2147/JIR.S477708Cao H, Ma X. Rituximab in the Treatment of Non-Infectious Uveitis: A Review. J Inflamm Res. 2024;17:6765–6780. doi: https://doi.org/10.2147/JIR.S477708Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int. 2020;40(10): 1717–1724. doi: https://doi.org/10.1007/s00296-020-04668-4Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int. 2020;40(10): 1717–1724. doi: https://doi.org/10.1007/s00296-020-04668-4Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. doi: https://doi.org/10.1080/09273948.2019.1605453Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. doi: https://doi.org/10.1080/09273948.2019.1605453Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi: https://doi.org/10.1007/s10067-019-04875-wMiserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi: https://doi.org/10.1007/s10067-019-04875-wEli Lilly and Company. A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis. Last Update Posted 2025-04-20. In: ClinicalTrials. gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04088409. Accessed on March 09, 2023.Eli Lilly and Company. A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis. Last Update Posted 2025-04-20. In: ClinicalTrials. gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04088409. Accessed on March 09, 2023.Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi: https://doi.org/10.1186/s13063-021-05651-5Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi: https://doi.org/10.1186/s13063-021-05651-5Wen J, Hu H, Chen M, et al. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. J Immunol Res. 2021;2021:2324400. doi: https://doi.org/10.1155/2021/2324400Wen J, Hu H, Chen M, et al. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. J Immunol Res. 2021;2021:2324400. doi: https://doi.org/10.1155/2021/2324400Proceedings of the 31st European Paediatric Rheumatology Congress: part 1. Pediatr Rheumatol. 2024;22(S2):82. doi: https://doi.org/10.1186/s12969-024-01004-zProceedings of the 31st European Paediatric Rheumatology Congress: part 1. Pediatr Rheumatol. 2024;22(S2):82. doi: https://doi.org/10.1186/s12969-024-01004-zNeves LM, Alves M. Juvenile Idiopathic Arthritis-Associated Uveitis: Evidence-Based Screening, Monitoring, and Treatment. In: Uveitis — Basics, Diagnosis, and Treatment [Working Title]. Feizi S, ed. 2023. doi: https://doi.org/10.5772/intechopen.110274Neves LM, Alves M. Juvenile Idiopathic Arthritis-Associated Uveitis: Evidence-Based Screening, Monitoring, and Treatment. In: Uveitis — Basics, Diagnosis, and Treatment [Working Title]. Feizi S, ed. 2023. doi: https://doi.org/10.5772/intechopen.110274Horton S, Jones AP, Guly CM, et al. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. Am J Ophthalmol. 2019;207: 170–174. doi: https://doi.org/10.1016/j.ajo.2019.06.007Horton S, Jones AP, Guly CM, et al. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. Am J Ophthalmol. 2019;207: 170–174. doi: https://doi.org/10.1016/j.ajo.2019.06.007Acharya NR, Ramanan AV, Coyne AB, et al. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025;405(10475):303–313. doi: https://doi.org/10.1016/S0140-6736(24)02468-1Acharya NR, Ramanan AV, Coyne AB, et al. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025;405(10475):303–313. doi: https://doi.org/10.1016/S0140-6736(24)02468-1Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. Am J Ophthalmol. 2015;160(1):193–200.e1. doi: https://doi.org/10.1016/j.ajo.2015.04.016Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. Am J Ophthalmol. 2015;160(1):193–200.e1. doi: https://doi.org/10.1016/j.ajo.2015.04.016Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222. doi: https://doi.org/10.1016/j.ajo.2010.08.021Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222. doi: https://doi.org/10.1016/j.ajo.2010.08.021Al-Haddad C, BouGhannam A, Abdul Fattah M, et al. Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center. BMC Ophthalmol. 2019;19(1):137. doi: https://doi.org/10.1186/s12886-019-1139-5Al-Haddad C, BouGhannam A, Abdul Fattah M, et al. Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center. BMC Ophthalmol. 2019;19(1):137. doi: https://doi.org/10.1186/s12886-019-1139-5Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1): 186–192. doi: https://doi.org/10.1016/j.ophtha.2012.07.052Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1): 186–192. doi: https://doi.org/10.1016/j.ophtha.2012.07.052Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk Factors for the Development of Cataract in Children with Uveitis. Am J Ophthalmol. 2017;177:139–143. doi: https://doi.org/10.1016/j.ajo.2017.02.023Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk Factors for the Development of Cataract in Children with Uveitis. Am J Ophthalmol. 2017;177:139–143. doi: https://doi.org/10.1016/j.ajo.2017.02.023Oray M, Khachatryan N, Ebrahimiadib N, et al. Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1841–1849. doi: https://doi.org/10.1007/s00417-016-3340-zOray M, Khachatryan N, Ebrahimiadib N, et al. Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1841–1849. doi: https://doi.org/10.1007/s00417-016-3340-zGautam Seth N, Yangzes S, Thattaruthody F, et al. Glaucoma Secondary to Uveitis in Children in a Tertiary Care Referral Center. Ocul Immunol Inflamm. 2019;27(3):456–464. doi: https://doi.org/10.1080/09273948.2017.1411517Gautam Seth N, Yangzes S, Thattaruthody F, et al. Glaucoma Secondary to Uveitis in Children in a Tertiary Care Referral Center. Ocul Immunol Inflamm. 2019;27(3):456–464. doi: https://doi.org/10.1080/09273948.2017.1411517Böhm MRR, Tappeiner C, Breitbach MA, et al. Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol. 2017;173:45–55. doi: https://doi.org/10.1016/j.ajo.2016.09.018Böhm MRR, Tappeiner C, Breitbach MA, et al. Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol. 2017;173:45–55. doi: https://doi.org/10.1016/j.ajo.2016.09.018Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150(4):534–542.e2. doi: https://doi.org/10.1016/j.ajo.2010.04.031Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150(4):534–542.e2. doi: https://doi.org/10.1016/j.ajo.2010.04.031Sen HN, Drye LT, Goldstein DA, et al. Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm. 2012;20(2):104–112. doi: https://doi.org/10.3109/09273948.2011.647228Sen HN, Drye LT, Goldstein DA, et al. Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm. 2012;20(2):104–112. doi: https://doi.org/10.3109/09273948.2011.647228Tran VT, Mermoud A, Herbort CP. Appraisal and management of ocular hypotony and glaucoma associated with uveitis. Int Ophthalmol Clin. 2000;40(2):175–203. doi: https://doi.org/10.1097/00004397-200004000-00014Tran VT, Mermoud A, Herbort CP. Appraisal and management of ocular hypotony and glaucoma associated with uveitis. Int Ophthalmol Clin. 2000;40(2):175–203. doi: https://doi.org/10.1097/00004397-200004000-00014Yangzes S, Seth NG, Singh R, et al. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019;67(4):490–495. doi: https://doi.org/10.4103/ijo.IJO_846_18Yangzes S, Seth NG, Singh R, et al. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019;67(4):490–495. doi: https://doi.org/10.4103/ijo.IJO_846_18Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6): 871–874. doi: https://doi.org/10.1136/ard.2004.026955Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6): 871–874. doi: https://doi.org/10.1136/ard.2004.026955Яковлев А.А., Гайдар Е.В., Белозеров К.Е. и др. Наличие увеита как показатель тяжести течения ювенильного идиопатического артрита: результаты ретроспективного когортного исследования // Педиатр. — 2023. — Т. 14. — № 2. — C. 37–47. — doi: https://doi.org/10.17816/PED14237-47Yakovlev AA, Gaidar EV, Belozerov KE, et al. Presence of uveitis as indicator of juvenile idiopathic arthritis severity: results of a retrospective cohort study. Pediatrician (St. Petersburg). 2023;14(2):37–47. (In Russ). doi: https://doi.org/10.17816/PED14237-47Skarin A, Berthold E, Rauer O, Bengtsson-Stigmar E. Uveitis associated with juvenile arthritis: a continued cohort study 40 years after uveitis onset. Pediatr Rheumatol Online J. 2022;20(1):47. doi: https://doi.org/10.1186/s12969-022-00704-8Skarin A, Berthold E, Rauer O, Bengtsson-Stigmar E. Uveitis associated with juvenile arthritis: a continued cohort study 40 years after uveitis onset. Pediatr Rheumatol Online J. 2022;20(1):47. doi: https://doi.org/10.1186/s12969-022-00704-8Skarin A, Elborgh R, Edlund E, Bengtsson-Stigmar E. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm. 2009;17(2): 104–108. doi: https://doi.org/10.1080/09273940802650398Skarin A, Elborgh R, Edlund E, Bengtsson-Stigmar E. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm. 2009;17(2): 104–108. doi: https://doi.org/10.1080/09273940802650398

The authors declare that there are no conflicts of interest present.